BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 24861577)

  • 1. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.
    Lerolle N; Raffoux E; Socie G; Touratier S; Sauvageon H; Porcher R; Bretagne S; Bergeron A; Azoulay E; Molina JM; Lafaurie M
    Clin Microbiol Infect; 2014 Nov; 20(11):O952-9. PubMed ID: 24861577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posaconazole prophylaxis--impact on incidence of invasive fungal disease and antifungal treatment in haematological patients.
    Peterson L; Ostermann J; Rieger H; Ostermann H; Rieger CT
    Mycoses; 2013 Nov; 56(6):651-8. PubMed ID: 23710592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
    Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
    J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
    Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
    Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
    Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
    J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
    Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
    Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
    Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
    Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
    Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study.
    Harrison N; Mitterbauer M; Tobudic S; Kalhs P; Rabitsch W; Greinix H; Burgmann H; Willinger B; Presterl E; Forstner C
    BMC Infect Dis; 2015 Dec; 15():584. PubMed ID: 26715563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil.
    Nucci M; Garnica M; Gloria AB; Lehugeur DS; Dias VC; Palma LC; Cappellano P; Fertrin KY; Carlesse F; Simões B; Bergamasco MD; Cunha CA; Seber A; Ribeiro MP; Queiroz-Telles F; Lee ML; Chauffaille ML; Silla L; de Souza CA; Colombo AL
    Clin Microbiol Infect; 2013 Aug; 19(8):745-51. PubMed ID: 23009319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.
    Herbrecht R; Caillot D; Cordonnier C; Auvrignon A; Thiébaut A; Brethon B; Michallet M; Mahlaoui N; Bertrand Y; Preziosi P; Ruiz F; Gorin NC; Gangneux JP
    J Antimicrob Chemother; 2012 Nov; 67(11):2731-8. PubMed ID: 22850692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation.
    Sun Y; Xu L; Liu D; Zhang X; Han W; Wang Y; Chen H; Chen Y; Wang F; Wang J; Ji Y; Tang F; Liu K; Huang XJ
    Clin Microbiol Infect; 2013 Nov; 19(11):1029-34. PubMed ID: 23565830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
    Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
    Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.
    Pagano L; Caira M; Candoni A; Aversa F; Castagnola C; Caramatti C; Cattaneo C; Delia M; De Paolis MR; Di Blasi R; Di Caprio L; Fanci R; Garzia M; Martino B; Melillo L; Mitra ME; Nadali G; Nosari A; Picardi M; Potenza L; Salutari P; Trecarichi EM; Tumbarello M; Verga L; Vianelli N; Busca A;
    Clin Infect Dis; 2012 Dec; 55(11):1515-21. PubMed ID: 22955439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole prophylaxis in neutropenic patients with hematological malignancies: limits in clinical practice.
    Bourdelin M; Grenouillet F; Daguindau E; Muret P; Desbrosses Y; Dubut J; Deconinck E; Limat S; Larosa F
    Med Mycol; 2014 Oct; 52(7):728-35. PubMed ID: 25012993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.
    Doan TN; Kirkpatrick CM; Walker P; Slavin MA; Ananda-Rajah MR; Morrissey CO; Urbancic KF; Grigg A; Spencer A; Szer J; Seymour JF; Kong DC
    J Antimicrob Chemother; 2016 Feb; 71(2):497-505. PubMed ID: 26518050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
    Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
    Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
    Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
    Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.